Oct 13, 2021 / 02:00PM GMT
Nathalie Delair-Trepo -
Good morning, good afternoon, bon jour. Welcome to this webcast to discuss SparingVision's strategic collaboration with Intellia Therapeutics. My name is Nathalie Trepo, Director of Investor Relations and Communications at SparingVision.
Earlier today, Intellia Therapeutics and SparingVision issued a press release detailing the terms of the strategic collaboration we will discuss today. This press release is available on the News section of the SparingVision website. Following today's prepared remarks, we will open up the call for questions. We, therefore, kindly ask that you keep your questions for the Q&A session.
We would also like to remind you that this call is being recorded. A replay will be made available on the SparingVision website.
With that, I will turn it over to Stéphane Boissel, Chief Executive Officer of SparingVision.
M. Stephane Boissel - SparingVision SAS - President, CEO & Chairman
Thank you, Nathalie. Good afternoon or good morning. I'm myself in California so it will be
Intellia Therapeutics Inc Strategic Collaboration to Develop Novel Genomic Medicines Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers